Aker BioMarine has signed an agreement with Trofi Nutritional Inc. (ôTrofiö) with the aim to develop medical foods products based on Lysoveta, targeting AlzheimerÆs disease, male infertility and gestational diabetes, in addition to pre-natal supplements in the US. According to the Center for Disease Control and Prevention (CDC), there is an increase in these diseases in the US population. Both increased life expectancy and lifestyle-related risk factors for these diseases are seen as contributions to this increase.

There are limited available therapeutical options in todayÆs healthcare system. Under the agreement, Aker BioMarine will license, with associated royalties on sales, relevant intellectual property rights and supply Lysoveta to Trofi, who will invest in clinical trials with the aim to develop and commercialize certain medical foods within the fields. Launch of first medical food and dietary supplement is planned for 2024.